Insider Buying: Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Purchases 1,353,625 Shares of Stock

Vivos Therapeutics, Inc. (NASDAQ:VVOS) major shareholder Michael Skaff acquired 1,353,625 shares of the business’s stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the acquisition, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Vivos Therapeutics Price Performance

NASDAQ:VVOS traded up $0.02 during mid-day trading on Thursday, reaching $1.32. 46,733 shares of the stock were exchanged, compared to its average volume of 124,929. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. The business has a fifty day moving average price of $1.45 and a 200 day moving average price of $2.15. Vivos Therapeutics, Inc. has a 1-year low of $1.09 and a 1-year high of $7.95. The firm has a market capitalization of $13.82 million, a PE ratio of -0.75 and a beta of 6.94.

Institutional Investors Weigh In On Vivos Therapeutics

Hedge funds have recently modified their holdings of the stock. DRW Securities LLC boosted its position in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the period. Connective Capital Management LLC purchased a new position in Vivos Therapeutics in the 3rd quarter worth about $620,000. B. Riley Wealth Advisors Inc. acquired a new stake in Vivos Therapeutics during the 2nd quarter worth about $220,000. XTX Topco Ltd purchased a new stake in Vivos Therapeutics during the second quarter valued at about $65,000. Finally, Acorn Wealth Advisors LLC purchased a new stake in Vivos Therapeutics during the fourth quarter valued at about $30,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on VVOS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Ascendiant Capital Markets reduced their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a report on Wednesday, December 3rd. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vivos Therapeutics presently has a consensus rating of “Hold” and an average price target of $4.92.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.